{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreas+Adenocarcinoma&page=2", "query": { "condition": "Metastatic Pancreas Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreas+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T05:26:06.169Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03126435", "title": "EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreas Cancer", "Locally Advanced Pancreatic Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "EndoTAG-1", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SynCore Biotechnology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2018-10-16", "completion_date": "2021-10-08", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 16, "location_summary": "Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126435" }, { "nct_id": "NCT00593008", "title": "Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-10", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2011-12-02", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593008" }, { "nct_id": "NCT06005493", "title": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastro-esophageal Junction Cancer", "Pancreatic Ductal Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "AZD5863", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-07-11", "completion_date": "2027-07-16", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • New York, New York", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005493" }, { "nct_id": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non Small Cell Lung", "Carcinoma, Pancreatic Ductal", "Malignant Melanoma", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "PF-08046037", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2025-05-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 14, "location_summary": "Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974734" }, { "nct_id": "NCT03323944", "title": "CAR T Cell Immunotherapy for Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "huCART-meso cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-09-15", "completion_date": "2025-02-20", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323944" }, { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT00049296", "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-07", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049296" }, { "nct_id": "NCT07344220", "title": "Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2026-01", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07344220" }, { "nct_id": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma" ], "interventions": [ { "name": "A166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-16", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 10, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602079" }, { "nct_id": "NCT01010126", "title": "Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Hepatocellular Carcinoma", "Advanced Adult Hepatocellular Carcinoma", "Endometrial Serous Adenocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Lung Carcinoid Tumor", "Malignant Pancreatic Gastrinoma", "Malignant Pancreatic Glucagonoma", "Malignant Pancreatic Insulinoma", "Malignant Pancreatic Somatostatinoma", "Metastatic Digestive System Neuroendocrine Tumor G1", "Ovarian Carcinosarcoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Pancreatic Alpha Cell Adenoma", "Pancreatic Beta Cell Adenoma", "Pancreatic Delta Cell Adenoma", "Pancreatic G-Cell Adenoma", "Pancreatic Polypeptide Tumor", "Recurrent Adult Liver Carcinoma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2009-09-08", "completion_date": "2017-03-13", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-07-24T05:26:06.169Z", "location_count": 57, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010126" } ] }